103909-75-7C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)OCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1ODTXXSJZBSTYZKE-ZDQKKZTESA-NMaxacalcitol is an organic molecular entity.
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Danger
H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]
P260, P262, P264, P270, P271, P280, P284, P301+P316, P302+P352, P304+P340, P316, P320, P321, P330, P332+P317, P361+P364, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 11 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Drugs used to treat or prevent skin disorders or for the routine care of skin.
Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved.
BeschreibungMaxacalcitol is the third synthetic vitamin D analog, after paricalcitol and doxercalciferol, to be marketed for the treatment of secondary hyperparathyroidism (SHPT) associated with chronic renal failure. It is a new vitamin D3 derivative with an oxygen atom in 22-position as main structural feature (22-oxacalcitriol, OCT). This vitamin D receptor agonist has a strong inhibitory effect on synthesis and secretion of parathyroid hormone in the setting of severe parathyroid hyperplasia. Maxacalcitol induced only minor effects on calcium and phosphate metabolism unlike an agent such as 1, 25(OH)2D3 that produced hypercalcemia and hyperphosphatemia. Maxacalcitol is.
Verwenden22-Oxacalcitriol is the noncalcemic analogue of vitamine D and was found to suppress parathyroid hormone synthesis and secretion.
103909-75-7DTXSID4048648CHEMBL333950CHEBI:31801